The 340B program, a drug discount program created by Congress through the Veterans Health Care Act of 1992,1 offers safety-net hospitals and other health care organizations eligible for 340B designation (“covered entities”) with large shares of low-income, vulnerable patients access to discounted drug pricing. This allows them to stretch resources to help more patients and provide more comprehensive services.2
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Kantarjian H, Chapman R. Value of the 340B Drug Discount Program. JAMA Oncol. 2015;1(8):1029–1030. doi:10.1001/jamaoncol.2015.2168
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: